| |
Therapeutic RNAs offer several advantages over other therapies due to their specificity and versatility, leading researchers to make great strides towards personalized medicine. Download the QPS white paper for insights into the future of RNA Therapies.
|
|
| By Max Bayer Bristol Myers Squibb is cutting $1.5 billion in costs through 2025, including layoffs to more than 2,000 employees in 2024. The pharma says it will reinvest the capital into high-performing assets. |
|
|
|
By Angus Liu Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles over in March. The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025. |
By Nick Paul Taylor Roche has performed a little light spring cleaning, sweeping a pair of phase 1 solid tumor drugs and an early-stage psychiatric disorder prospect out of the door as part of its update for the first quarter. The culls are part of a broader refocusing that has removed 20% of new molecules from the pipeline in recent quarters. |
By Max Bayer Sanofi's global restructuring is becoming clearer, with employees in Belgium the latest to be impacted. The French pharma expanded its footprint in Ghent after acquiring Ablynx in 2018. |
By Joseph Keenan Par Pharmaceucital, a unit of Endo, issued a voluntary recall of 7 lots of the injectable high blood pressure medication treprostinil due to the possible contamination of silicon particles in the solution. |
By Andrea Park As industries around the globe wrestle with where and how often artificial intelligence should be implemented in their workflows, biopharma, for one, is proceeding with caution. |
By Kevin Dunleavy Sanofi will pay approximately $25,000 per person to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (ranitidine) can cause cancer, Bloomberg reported. |
By Conor Hale Profluent has staked a claim at the intersection of some of the buzziest terms in biopharma. The protein-focused AI startup believes its large language models can help extend the reach of CRISPR gene editing tools. |
By Helen Floersh A new study adds to the case that long-term daily aspirin use may prevent colorectal tumors from developing or spreading in some patients, with potential implications for future drugs. |
By Nick Paul Taylor Immunology is AbbVie’s world, everyone else just lives in it. That is the takeaway from ZoomRx’s analysis of the perceptions of healthcare professionals , who overwhelmingly see AbbVie as the top dog in a field targeted by rivals such as Pfizer and Johnson & Johnson. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we are joined by Annalee Armstrong, Senior Editor at Fierce Biotech, and Ben Adams, Senior Editor of Fierce Pharma Marketing, to discuss Fierce's take on March Madness. |
|
|---|
|
|
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| WhitepaperAntibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| eBook Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain. Download this eBook to learn more about the future state of health care dynamics and its affects along the pharmaceutical value chain. Presented by Optum Life Sciences and Advisory Board |
| Executive SummaryLearn about the current state of biopharma logistics with insights from 150 manufacturers in this exclusive market survey report. Download the report to learn about how regulatory factors and emerging therapies are having an effect on logistics. Sponsored by: Cardinal Health 3PL Services |
| eBookUnlock the future of monoclonal antibody (mAb) manufacturing with a complete guide to enhancing productivity and quality for exceptional outcomes. Sponsored by: Thermo Fisher Scientific |
| WhitepaperClinical trials demand accurate lab data. Central labs uphold standards by ensuring consistency in methodologies, equipment, and reporting. Robust and integrated analytical platforms can support this via real-time access to study and lab data with transparent reporting capabilities, as well as to facilitate critical clinical decision-making and solve drug developers' challenges. Learn more about Preclarus®️ Lab Solutions by PPD®️ from expert Chris Clendening in this paper. Sponsored by: PPD®️ Laboratory Services |
| WhitepaperThis paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperChoosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
| WhitepaperSelecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. Sponsored by: BioCare |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
